Intercell agrees on a marketing and distribution agreement for its Japanese Encephalitis Vaccine
Advertisement
Intercell AG announced that it has agreed the principle terms of a marketing and distribution agreement with Novartis for its Japanese encephalitis Vaccine in the market for travellers in the United States, Europe and certain other markets in Asia and Latin America where the product is not partnered yet.
Intercell´s Japanese Encephalitis Vaccine (IC51) is a modern cell culture based vaccine which is manufactured in Intercell´s manufacturing plant in Scotland. Intercell will retain all development and production rights and will continue to lead the global development and regulatory pathway. Intercell has recently announced positive results for IC51 in a pivotal Phase III clinical trial and expects US and EU approval in 2007 and 2008, respectively.
In connection with the marketing and distribution agreement for IC51, Intercell will receive milestone payments of up to EUR 37 million from Novartis, depending on final Phase III clinical trial data as well as US and EU regulatory approvals. Furthermore, Novartis will make an equity investment of up to EUR 30 million in Intercell's shares, which will also give Novartis the first negotiation rights to certain existing product candidates derived from Intercell's technology platform.
Intercell intends to initially distribute IC51 in the market for the armed forces and military personnel on its own with the US Army expected to be a key customer. For the marketing and distribution of the vaccine in Australia, where the disease is endemic, Intercell has partnered with CSL Ltd. For marketing and distribution in certain endemic countries in Asia, Intercell has entered into a strategic partnership with the Indian company Biological E. Ltd.
Other news from the department research and development
